Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma (“Remarkably better” results)

Medical Xpress / Impact Journals / Oncotarget ^ | Dec. 13, 2022 | Francis R. LeBlanc et al

[ConservativeMind]

A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.

Classical MCL (cMCL) constitutes 6-8% of all B cell non-Hodgkins lymphoma (NHL). Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer subtype of cMCL associated with an aggressive clinical course and poor treatment response, frequent relapse and poor outcomes.

In this new study, researchers treated 13 bMCL patients with combined epigenetic and immunotherapy treatment consisting of vorinostat, cladribine and rituximab (SCR).

"We report an increased OS [overall survival] greater than 40 months with several patients maintaining durable remissions without relapse for longer than 5 years," write the researchers.

These results are remarkably better than current treatment regimens, which in bMCL, range from 14.5-24 months with conventional chemotherapy regimens. The researchers demonstrate that the G/A870 CCND1 polymorphism is predictive of blastic disease, nuclear localization of cyclinD1 and response to SCR therapy. The major resistance mechanisms to SCR therapy are loss of CD20 expression and evasion of treatment by sanctuary in the CNS. These data indicate that administration of epigenetic agents improves efficacy of anti-CD20 immunotherapies.

The researchers conclude, "This approach is promising in the treatment of MCL and potentially other previously treatment refractory cancers."

[ConservativeMind]

Good news for a bad lymphoma.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[Candor7]

Ping for Ro

[icclearly]

I have MCL and in remission. There are many good options for treatment if you see a real expert in the disease.

[Fred Nerks]

Difuse large cell non-hodgekins lymphoma. Currently in remission. On the long list of people in a class action against Bayer/Monsanto. Manufacturers of Roundup...glyphosate weed killer.

[Candor7]

That’s really good news!